Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation
- 1 March 2011
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 81 (5), 649-660
- https://doi.org/10.1016/j.bcp.2010.12.014
Abstract
No abstract availableKeywords
Funding Information
- Cropsolutions, Inc. (DK068962)
- National Institutes of Health (DK43220)
- National Institute for Food and Agriculture (2009-65200-05846)
- American Diabetes Association (7-06-RA-103)
This publication has 63 references indexed in Scilit:
- Elevated hepatic fatty acid elongase-5 activity corrects dietary fat-induced hyperglycemia in obese BL/6J miceJournal of Lipid Research, 2010
- Fatty acid metabolism: target for metabolic syndromeJournal of Lipid Research, 2009
- Inhibition of Gluconeogenesis in Primary Hepatocytes by Stromal Cell-derived Factor-1 (SDF-1) through a c-Src/Akt-dependent Signaling PathwayJournal of Biological Chemistry, 2008
- The role of exercise and PGC1α in inflammation and chronic diseaseNature, 2008
- N-3 polyunsaturated fatty acid regulation of hepatic gene transcriptionCurrent Opinion in Lipidology, 2008
- Novel isolation procedure for short-, medium-, and long-chain acyl-coenzyme A esters from tissueAnalytical Biochemistry, 2008
- Docosahexaenoic acid (DHA) and hepatic gene transcriptionChemistry and Physics of Lipids, 2008
- Continuous fat oxidation in acetyl–CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivityProceedings of the National Academy of Sciences, 2007
- Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesityJournal of Lipid Research, 2006
- Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasisProceedings of the National Academy of Sciences, 2006